OCUP - Ocuphire Pharma, Inc. Stock Price, Fair Value and News

$0.99+0.16 (+19.28%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

OCUP Price Action

Last 7 days

-8.1%

Last 30 days

-5.6%

Last 90 days

-21.5%

Trailing 12 Months

-61.4%

OCUP RSI Chart

OCUP Valuation

Market Cap

31.3M

Price/Earnings (Trailing)

-1.15

Price/Sales (Trailing)

3.73

EV/EBITDA

0.2

Price/Free Cashflow

-2.3

OCUP Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

OCUP Fundamentals

OCUP Revenue

Revenue (TTM)

8.4M

Rev. Growth (Yr)

-67.6%

Rev. Growth (Qtr)

247.75%

OCUP Earnings

Earnings (TTM)

-27.2M

Earnings Growth (Yr)

-235.34%

Earnings Growth (Qtr)

3.08%

OCUP Profitability

EBT Margin

-324.47%

Return on Equity

-79.28%

Return on Assets

-67.33%

Free Cashflow Yield

-43.48%

OCUP Investor Care

Shares Dilution (1Y)

39.45%

Diluted EPS (TTM)

-1.08

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	19.0M	16.4M	8.4M	0
2023	34.6M	29.4M	24.2M	19.0M
2022	0	0	0	39.9M
2021	0	1.3M	589.0K	20.2M
2020	0	0	0	0
2019	0	0	0	0
2018	0	0	0	0
2017	0	0	0	0
2016	0	0	0	0
2015	0	0	0	0
2014	0	0	0	0
2013	0	0	0	0
2012	0	0	0	0
2011	0	0	0	0
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Ocuphire Pharma, Inc.

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate for dim light or night vision disturbances; and for pharmacologically induced mydriasis and presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. The company is headquartered in Farmington Hills, Michigan.

CEO	Mr. Richard J. Rodgers M.B.A.
WEBSITE	ocuphire.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	9

Ocuphire Pharma, Inc. Frequently Asked Questions

What is the ticker symbol for Ocuphire Pharma, Inc.? What does OCUP stand for in stocks?

OCUP is the stock ticker symbol of Ocuphire Pharma, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ocuphire Pharma, Inc. (OCUP)?

As of Thu Dec 19 2024, market cap of Ocuphire Pharma, Inc. is 31.25 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OCUP stock?

You can check OCUP's fair value in chart for subscribers.

Is Ocuphire Pharma, Inc. a good stock to buy?

The fair value guage provides a quick view whether OCUP is over valued or under valued. Whether Ocuphire Pharma, Inc. is cheap or expensive depends on the assumptions which impact Ocuphire Pharma, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OCUP.

What is Ocuphire Pharma, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Dec 19 2024, OCUP's PE ratio (Price to Earnings) is -1.15 and Price to Sales (PS) ratio is 3.73. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OCUP PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Ocuphire Pharma, Inc.'s stock?

In the past 10 years, Ocuphire Pharma, Inc. has provided -0.441 (multiply by 100 for percentage) rate of return.